Inspirna, Tebra, RefleXion
Ganymed Robotics brings home €21 million to launch surgical robots
French startup that develops computer vision software and robotics technologies for orthopaedic surgeons, Ganymed Robotics has raised €21 million in funding. The oversubscribed Series B round was led by Cathay Health, with participation from Credit Mutuel Innovation, Kurma Partners, BNP Paribas Développement and internationally renowned surgeons.
The funding will be used to support Ganymed’s expansion in France and in the U.S., finalise the industrial development of its surgical robotic assistant for knee arthroplasty (TKA), accelerate regulatory and marketing developments across geographies and diversify the product pipeline.
Founded in 2018, Ganymed Robotics aims to empower orthopaedic surgeons in the operating room. Its first application is a co-manipulated surgical robotic assistant for TKA. The company claims the compact and intuitive robot simplifies and increases the accuracy of orthopedics.
Ganymed Robotics brings home €21 million to launch surgical robots - Tech.eu
The funding will be used to support the French startup’s expansion in the U.S. and finalise the industrial development of its surgical robotic assistant for knee arthroplasty
RefleXion Closes $125M Debt Facility
RefleXion Medical, a Hayward, CA-based therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, closed a $125M debt facility led by Oxford Finance.
$55M is available immediately to repay the company’s existing $50M of debt. The remaining $70M of the new facility will be made available upon reaching certain regulatory and commercial milestones.
RefleXion is a privately-held company developing the first biology-guided radiotherapy system. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.
The funds will support the continued commercialization of the RefleXion X1 platform and the introduction of RefleXion’s novel BgRT technology.
RefleXion Closes $125M Debt Facility
RefleXion Medical, a Hayward, CA-based therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, closed a $125M debt facility
Tebra Secures More Than $72M in Funding at Over $1 Billion Valuation
Tebra, a Newport Beach, CA-based provider of a digital platform for independent healthcare practices, raised $72M in growth equity and debt financing at over $1 Billion valuation.
The round was led by Golub Capital. Tebra’s institutional investors also include CommonFund, HLM Venture Partners, OpenView Venture Partners, StepStone Group, Stripes Group, Montreux Equity Partners, Toba Capital, Transformation Capital and Vivo Capital.
The company intends to use the funds to accelerate its merger plans including expanding its market share, developing and launching the combined product line and advancing the new branding.
Led by CEO Dan Rodrigues, Tebra provides digital tools and support to enable independent healthcare practices to attract patients, deliver care, get paid, and operate. Built through the combination of Kareo and PatientPop, the offering includes modern websites, messaging and scheduling, telehealth, EHR, care delivery, practice management, billing, payments, and analytics. Since the companies merged in late 2021, the company has built and launched a two-way product integration that allows both platforms to share scheduling information and physician availability. The integrated solution also reviews appointment information and sends out surveys for better reputation management. Over 800 providers now use the combined operating system, and the company plans to grow significantly both into their existing base and the healthcare industry at large.
Tebra Secures More Than $72M in Funding at Over $1 Billion Valuation
Tebra, a Newport Beach, CA-based provider of a digital backbone for independent healthcare practices, raised $72M in funding
Inspirna Raises $50M in Series D Financing
Inspirna, a New York-based clinical stage biopharmaceutical company, raised $50M in Series D funding.
The round was led by Sands Capital and Vivo Capital, with participation from Dreavent 6, Novo Holdings A/S, Sofinnova Partners, Sixty Degree Capital Fund, New York City Investment Fund LLC, and Lepu Holdings. In addition, Michael Ginder, of Sands Capital, and Jack Nielsen, of Vivo Capital, will join Inspirna’s Board of Directors.
Led by CEO Masoud Tavazoie, Inspirna is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Its lead drug candidate, RGX-202-01, is an orally-administered small molecule that targets the CKB/SLC6A8 pathway. This pathway becomes activated in the tumors of select patients where it enables the generation of the energy molecule ATP in response to tumor hypoxia. In addition, the company is advancing RGX-104, an oral small molecule activator of LXR/APOE that inhibits angiogenesis and tumor myeloid derived suppressor cells to enhance the immune response against tumors. RGX-104 is currently being tested in a Phase 1b/2 clinical trial in APOE biomarker enriched patients with advanced or metastatic lung cancer or endometrial cancer.
Inspirna Raises $50M in Series D Financing - FinSMEs
Inspirna, a New York-based clinical stage biopharmaceutical company, raised $50M in Series D funding
ClinChoice Raises $150M in Series E Funding
ClinChoice, a Philadelphia, PA- and Shangai, China-based clinical CRO company, raised $150M in Series E funding.
The round wasted by Legend Capital, with participation from Taikang Life Insurance, Sherpa Healthcare Partners, Lilly Asia Ventures and Apricot Capital.
The company intends to use the funds to fund its continued business expansion and innovative service offering worldwide.
Led by CEO Mr. Ling ZHEN, ClinChoice provides a clinical CRO that integrates One-stop Service Offerings for new bio-pharmaceutical and medical device clients worldwide. Their Service Offerings cover Clinical Operation, Project Management, Biostatistics, Data Management, Biostatistical Programming, Regulatory Affairs, Medical Affairs, Feasibility Research, HGRAC Submission, Clinical Safety Management, Site Management Organization, Nature Medicine/Traditional Chinese Medicine and Phase I Clinical Research.
